Japan is gripped by its worst disaster since WWII, with the devastating earthquake, tsunami and now nuclear radioactivity fears.Mike Trees, who founded TCL Sports in 2005, has over 25 years of experience in triathlon as both a professional triathlete and a coach to elite triathletes, and has a close bond with the country.Mike and his Japanese wife Rieko have lived in Japan for many years and have family and friends there. On Friday 11 March 2011, they watched in horror when the earthquake and tsunami hit Eastern Japan.“We instantly knew we had to do something. One of the port towns called Kamaishi was literally washed away in front of our eyes.”So, Mike has launched Tri 4 Japan to mobilise the triathlon community into taking action.Kamaishi International Triathlon has been at the forefront of triathlon in Japan for over 22 years. To name just a few pros, Cameron Brown, Lorretta and Luke Harrop, Rina Bradshaw Hill, Glende Magnum, Chris Hill, Stephen Farrell, Jason Metters and Mike Trees, have all raced there. All these athletes were able to make a living in the sport of triathlon thanks to the generous sponsorship of such races.Kamaishi International Triathlon was funded totally by the Town Council. Now the town has been devastated and that same council and town needs support.The mission of Tri 4 Japan is clearly stated by Mike:“I want all triathletes around the world to dig deep and help Tri4Japan raise money. Triathlon in Japan has enriched the lives of so many triathletes for over 25 years, now I want all our friends in the triathlon world to help Japan.“Our aim is to raise as much money as possible by September. No expenses will be taken, and all people helping are offering their time and services for free. The money will really help but also the psychological boost to the Japanese, knowing that all triathletes around the world are helping will be priceless.“Rieko and I intend to get to the devastated area as soon as it is safe to do so.“We will research and analyse what Japan needs most and we would like to use it for their best, as we realise many will now be orphaned due to the tsunami; we want our money to help people who have lost their family members through this disaster. “Tri 4 Japan will raise money by the following:1. Selling T-shirts; all money raised will go to the charity 2. Events to help raise money, in both Japan and the UK (Tri 4 Japan needs other countries on board) 3. Via the UK and international triathlon scene, running, cycle shops etc., to help raise moneyBefore sending out its mission statement, the initial response to Tri 4 Japan has been tremendous. Lloyds Bank TSB, Newton Running, GU Energy, 2XU, Blue Seventy, OpenWaterSwim.co.uk, Triathlete magazine UK, Tri247.com have all pledged support. This list is just the start and Tri 4 Japan needs many more companies on board.The newly formed Tri 4 Japan charity will be in a position to take money and pledges in around two weeks. As Mike notes on the new Tri 4 Japan website:“At present it is just Rieko and I, so we need help to get this appeal to build momentum. Remember what thought did? NOTHING!!!!…he just thought he did it! We are all busy, but must make the effort, don’t be like thought.”www.tri4japan.com Related
Eat Fit Go’s new outlet in Corinth Square specializes in pre-prepared meals emphasizing health ingredients.Eat Fit Go Healthy Foods, a new prepared food chain based in Omaha, plans to open the first of at least three Kansas City area stores at Corinth Square by December.The 1,000 square-foot store in Prairie Village will stock a wide variety of healthy meals prepared at a new central kitchen under construction in the Kansas City area, said Sara Huse, director of brand management.“We are really excited to be in Kansas City,” she said. “We feel there’s a need for a food revolution and people need healthy choices.”While there will be tables and a microwave should customers decide to eat at the new venue, most people will pick up pre-prepared meals to dine at home.The refrigerators are stocked with fresh meals that contain no preservatives, low sodium, high protein and allergy friendly. Huse said almost all of the meals have fewer than 600 calories.“It’s a convenient way to eat healthy on the go,” she said.Eat Fit Go was started by Aaron McKeever and Sam Vakhidov and its first store opened in Omaha in February. There are now three in Omaha, one in Lincoln and another opening in Norfolk, Neb.Kansas City is the firm’s first venture outside the Cornhusker State, and additional stores also are expected to open in the Phoenix area.
Atlona has begun shipping the AT-OME-MS52W 5×2 matrix switcher. The OME-MS52W features HDMI, DisplayPort and USB-C inputs alongside mirrored or matrixed HDBaseT and HDMI outputs with selectable switching modes. All wired AV inputs and the local HDMI output support High Dynamic Range (HDR) formats and 4K@60Hz (4:4:4) video at HDMI data rates up to 18 gigabits per second. Native, platform-based, wireless interfacing enables screen mirroring for iOS, Android, Mac, Chromebook and Windows devices without the need for a separate app, while moderator functionality, accessible through the OME-MS52W’s web interface enables an authorized user to preview, allow or block content from up to 16 wirelessly connected devices.The OME-MS52W supports HDBaseT transport of video up to 4K@60Hz with 4:2:0 chroma subsampling alongside embedded audio, control, Ethernet and — when paired with a USB-capable Omega Series receiver such as the AT-OME-EX-RX or AT-OME-SR21 — USB data. Combined with USB 2.0 and USB-C interfaces for up to three host PCs and two peripheral devices, this USB extension capability makes the OME-MS52W an ideal integration solution for software videoconferencing and unified communications applications including Zoom, Skype for Business, Microsoft Teams, Cisco Webex, BlueJeans and GoToMeeting.The OME-MS52W can automatically switch between inputs when sources are connected or removed, while automatic display control turns compatible monitors and projectors on or off without user intervention. Other integration features include audio embedding and de-embedding; motorized screen or display lift activation; and trigger I/O ports to power the system up or down based on occupancy sensing. The switcher can be remotely managed through the Atlona Management System or Atlona’s innovative Velocity IP-enabled AV control platform, while TCP/IP and RS-232 support enable integration with third-party control systems.
Caribbean chikungunya cases top 1,400The count of confirmed and probable chikungunya cases on Caribbean islands and neighboring areas reached 1,446 late last week, a spike of 411 cases in only 4 days, the European Centre for Disease Prevention and Control (ECDC) reported on Feb 7.The ECDC said St. Martin has reached 601 cases on the French side of the island, an increase of 125 cases, and 60 on the Dutch side, which saw a dramatic 51-case increase.Other areas in the region now have the following case totals, the agency said: Martinique, 518 (154 new cases); Guadeloupe, 175 (56 new); Saint Barthelemy, 83 (27); British Virgin Islands, 6 (3); and Dominica, 3, plus 1 imported case. The ECDC also reported 4 imported cases in French Guyana in northeastern South America and 1 imported case each on the islands of Aruba and Anguilla.The outbreak, which began on St. Martin in early December 2013, is the first known instance of indigenous cases of the mosquito-borne disease in the Americas. The new total is 411 more than the 1,035 cases reported by the ECDC on Feb 3.Feb 7 ECDC update Feb 3 CIDRAP News scan on previous ECDC report CDC estimates West Nile hospital cases cost almost $800 millionResearchers from the Centers for Disease Control and Prevention (CDC) in a study today estimate that hospitalized cases of West Nile virus (WNV) infection in the United States since the disease was introduced in 1999 have cost $778 million in healthcare expenses and lost productivity.Writing in the American Journal of Tropical Medicine and Hygiene, published by the American Society of Tropical Medicine and Hygiene (ASTMH), the researchers said they determined the expense of initial hospitalization for 80 patients during a 2003 WNV outbreak in Colorado. For a subset of the patients, they then calculated costs of additional related medical care and missed work incurred in the 5 years after the initial infection.To estimate the total US cost of WNV disease, then, the investigators extrapolated those costs to the total number of hospitalized cases of WNV disease reported to the CDC since 1999. Those findings suggest an annual burden of $56 million, or $778 million over the 14 years (95% confidence interval, $673 million to $1.1 billion).This is the first published study to calculate hospital costs for the four specific “clinical syndromes” of the disease: fever, meningitis, encephalitis, and acute flaccid paralysis, the ASTMH said in a press release.Since 1999, 37,088 WNV cases have been reported to the CDC, the ASTMH said, including more than 18,000 hospitalizations and 1,500 deaths. The CDC said that WNV patients over 50 are more likely to develop severe neurologic disease.”We believe that previous costs associated with West Nile virus disease have been underestimated because they’ve predominantly focused on the costs of the initial illness,” said J. Erin Staples, MD, PhD, the study’s lead author.Feb 10 Am J Trop Med Hygiene abstract Feb 10 ASTMH news release Feb 10 Am J Trop Med Hygiene commentary on the study Report says local health department jobs down 12%Local health departments (LHDs) have shed the equivalent of 20,000 full-time workers, or about 12%, in 5 years, according to a new report from the National Association of County and City Health Officials (NACCHO).NACCHO researchers surveyed all 2,532 LHDS in its database from January through March 2013 and received a response from 2,000 of them, for a 79% response rate. Only Massachusetts (40%) and Indiana (59%) had response rates below 60%. The organization has conducted such an LHD “profile” survey every 3 years since 2005, and less often before that.The survey data revealed that the LHD workforce, in full-time equivalents, dropped from 166,000 in 2008 to 146,000 in 2013, and from 190,000 workers overall to 162,000, the report said.A separate NACCHO report last September found that LHDs have lost 43,900 jobs since 2008 owing to layoffs and attrition.The survey also found that funding for LHD preparedness activities dropped from $2.07 per person in 2010 to $1.15 per person in 2013. The report noted, however, that 87% of LHDs have developed or updated a written emergency plan, while 76% have participated in tabletop exercises or drills.On the upside, 56% of LHDs now have formal quality improvement programs, compared with just 45% in 2010.”This 2013 Profile report is a valuable resource for all public health professionals, policymakers, federal agencies, researchers and others to use to understand our nation’s current local public health infrastructure,” said CDC Director Tom Frieden, MD, MPH, in a news release today from the American Public Health Association (APHA).Feb 10 APHA news release NACCHO’s LHD profile report Profile report landing page Sep 12, 2013, CIDRAP News scan on previous NACCHO report Polio eradication effort receives $100 million giftA planned gift of $100 million toward the Global Polio Eradication Initiative’s (GPEI’s) fund-raising goal of $5.5 billion to eradicate polio worldwide by 2018 has been announced by the Lawrence Ellison Foundation, according to a recent PR Newswire press release. A total of $4 billion has been pledged so far by governments and private donors.About $20 million of the Ellison donation was delivered in 2013, says the release. The gift brings to 10 the number of philanthropies that committed $535 million, and the Bill & Melinda Gates Foundation has pledged another $1.8 billion.Polio remains endemic in only three countries, Afghanistan, Pakistan, and Nigeria, compared with 125 as recently as 1988. The lowest-ever number of new wild poliovirus cases worldwide occurred in 2012, but outbreaks occurred in five previously polio-free countries in 2013, including conflict-ridden Syria and the Horn of Africa.Vaccination efforts in northwest Pakistan and northern Nigeria have proved difficult because of security issues for healthcare workers and even for the law-enforcement personnel guarding them. Despite this, however, the number of new cases in Nigeria was reduced by 65% in 2013 compared with 2012 and in Afghanistan by 65%. Also in 2013, India, once thought to be the most difficult place to eradicate polio, was declared polio-free after having no new wild polio cases for 3 years.Feb 8 PR Newswire press release
The results of two phase 3 clinical trials reported this week in the New England Journal of Medicine indicate that omadacycline, a recently approved, modified tetracycline antibiotic, is as effective as standard antibiotics for treating community-acquired pneumonia and skin infections.The two double-blind, randomized, noninferiority trials were conducted at sites in several countries and designed and supported by drug developer Paratek Pharmaceuticals of Boston, Mass. In one of the trials, omadacycline was found to be noninferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia. In the other, omadacycline was found to be noninferior to linezolid for the treatment of acute bacterial skin and skin-structure infections, with a similar safety profile.The US Food and Drug Administration approved omadacycline (marketed as Nuzyra) for the two conditions in October 2018, after reviewing the results of these two trials and previous clinical studies. The drug, which comes in intravenous (IV) and oral formulations, is a “modernized” tetracycline that’s designed to overcome tetracycline resistance and has shown activity against both gram-positive and gram-negative bacteria, including antibiotic-resistant strains. Community-acquired bacterial pneumonia is one of the most common infectious causes of illness and hospitalization, especially in the elderly, and incidence of bacterial skin and skin-structure infections has been rising. Paratek officials say increasing drug-resistance in the pathogens that cause these infections highlights the importance of the trial results.”These pivotal clinical trials demonstrated that Nuzyra is an effective, well-tolerated monotherapy option for patients with activity across an appropriate spectrum of bacteria, including gram-positive, gram-negative, atypicals, and drug-resistant strains, and we believe Nuzyra can play an important role in winning the battle against the growing health challenge of antibiotic resistance,” Paratek Pharmaceuticals president Evan Loh, MD, said in a company press release.But some infectious disease physicians are questioning what the role of the new drug will be.Trials demonstrate noninferiorityIn the OPTIC (Omadacycline for Pneumonia Treatment in the Community) trial, researchers enrolled adult patients with community-acquired bacterial pneumonia at 86 sites in Europe, North America, South America, the Middle East, Africa, and Asia. Patients were randomly assigned, on a 1:1 basis, to receive IV omadacycline or IV moxifloxacin for 7 to 14 days, with a transition to oral versions of the two drugs allowed after 3 days.The primary endpoint of the trial was early clinical response, defined as survival with improvement in at least two of four symptoms (cough, sputum production, pleuritic chest pain, and dyspnea) and no worsening of symptoms at 72 to 120 hours. Secondary endpoints included investigator-assessed clinical response at post-treatment evaluation 5 to 10 days after the last antibiotic dose. The noninferiority margin was 10 percentage points.Of the 774 patients, 386 received omadacycline and 388 received moxifloxacin. The results showed that 81.1% of patients in the omadacycline arm had an early clinical response, compared with 82.7% of patients in the moxifloxacin arm (difference, –1.6; 95% confidence interval [CI], –7.1 to 3.8), demonstrating noninferiority. The rates of investigator-assessed clinical response at 5 to 10 days post-treatment were 87.6% for omadacycline and 85.1% for moxifloxacin (difference, 2.5 percentage points; 95% CI, –2.4 to 7.4).Evaluation of safety found that adverse events emerged after treatment in 41.1% of the omadacycline patients and 48.5% of the moxifloxacin patients. The most frequent were gastrointestinal (10.2% in the omadacycline arm and 18.0% in the moxifloxacin arm), with the biggest difference observed in incidence of diarrhea (1% in the omadacycline group and 8% in the moxifloxacin group). Twelve deaths occurred during the trial, with 8 deaths occurring in the omadacycline arm and 4 in the moxifloxacin arm. The authors of the study note that they were not able to establish reasons for the difference in the mortality rate.In OASIS-1 (the Omadacycline in Acute Skin and Skin-Structure Infections Study), researchers at 55 sites in Europe, the United States, Peru, and South Africa enrolled adults with a qualifying skin infection (including wound infections, cellulitis, or major abscesses) and randomly assigned them 1:1 to receive 7 to 14 days of IV omadacycline or IV linezolid, with the option to switch to oral versions of the drugs after 3 days. A total of 655 patients underwent randomization, with 627 included in the modified intention-to-treat population (316 in the omadacycline arm and 311 in the linezolid arm).The primary endpoint was early clinical response at 48 to 72 hours, and the secondary endpoint was investigator-assessed clinical response 7 to 14 days after treatment ended. The noninferiority margin was 10 percentage points.Again, omadacycline was found to be noninferior, with 84.8% of patients in the omadacycline group showing early clinical response, compared with 85.5% in the linezolid group (difference, –0.7 percentage points; 95% CI, –6.3 to 4.9). The results were similar for the secondary endpoint. The investigator-assessed clinical response post-treatment was 86.1% in omadacycline patients and 83.6% in those treated with linezolid (difference, 2.5 percentage points; 95% CI, –3.2 to 8.2). In addition, omadacycline was as effective as linezolid against both methicillin-susceptible and methicillin-resistant Staphylococcus aureus, a common cause of bacterial skin infections.Adverse events were reported in 48.3% of the patients in the omadacycline group and 45.7% in the linezolid group. The most frequent adverse events were gastrointestinal (18% in the omadacycline arm and 15.8% in the linezolid arm), and most were mild.Questions about clinical valueIn an editorial that accompanies both studies, Henry Chambers, MD, an infectious disease specialist at Zuckerberg San Francisco General Hospital, writes that while both trials are high quality and clearly demonstrate that omadacycline has similar efficacy to the standard-of-care agents, the clinical value of the new drug is unclear.”Omadacycline has few advantages over the numerous agents already available for treatment of acute bacterial skin and skin-structure infections,” Chambers writes. “A similar analysis pertains to community-acquired bacterial pneumonia, for which there are several effective treatment options, although omadacycline may offer some advantages.”That sentiment is echoed by Andrew Morris, MD, medical director of the Sinai Health System-University Health Network Antimicrobial Stewardship Program and a professor of medicine at the University of Toronto. “We don’t need new drugs for community-acquired pneumonia and skin and soft-tissue infections. There are a plethora of agents available,” Morris told CIDRAP News. “Antimicrobial resistance is rarely an issue in these conditions, and omadacycline’s characteristics add absolutely nothing to what is available, which includes doxycycline.”For Chambers, the big question is whether omadacycline will be effective against other types of infections caused by multidrug-resistant gram-negative pathogens, particularly those that are carbapenem resistant. That question remains unanswered.While the drug is a promising candidate for treating infections caused by carbapenem-resistant Enterobacteriaceae and species of Acinetobacter, Chambers writes, well-designed clinical trials testing omadacycline against these and other multidrug-resistant gram-negative organisms “are needed to determine its real value as an antibacterial agent.”See also:Feb 6 N Engl J Med OPTIC trialFeb 6 N Engl J Med OASIS-1 trialFeb 6 N Engl J Med editorialFeb 6 Paratek Pharmaceuticals press release
LSI President Brett Tennar says, “Steve’s success in developing operational strategies that improves the bottom line, builds teamwork, reduces waste and ensures quality product development and distribution checks many of the boxes of what we were looking for in a COO. This, coupled with his career in the Air Force working with highly technical systems and his in-depth understanding of Lean Six Sigma and Business Process Management sealed our offer. As our tagline states, our products are Powered by Science. This data driven approach is one reason why our company has grown exponentially as we employ the most advanced technology to product development. I am confident that Steve is the right person to drive operational strategy for our diverse and growing brands.” Advertisement DeMoulpied has a Bachelor of Science degree in Engineering Management from the United States Air Force Academy and a Master of Business Administration degree from the University of Dayton in Marketing and International Business. He served six years with the USAF overseeing the development of technology used on fighter aircraft and the E-3 Surveillance aircraft, finishing his career honorably as Captain. DeMoulpied comes to LSI from the Private Client Services practice of Ernst & Young where he managed strategy & operations improvement engagements for privately held client businesses. Some of his prior roles include VP of strategic development, director of strategic initiatives, and Lean Six Sigma Master Black Belt at OptumHealth, UnitedHealth Group’s health services business, as well as Lean Six Sigma Black Belt at General Electric, where he applied operations improvement principles to customer service, supply chain and product development. A successful entrepreneur, deMoulpied is also the founder of PrestoFresh, a Cleveland-based e-commerce food/grocery business. With more than 20 years of experience across multiple industries and functional areas, deMoulpied has particular expertise in organizations with complex technical products. Combined, his prior positions have required a spectrum of skills in corporate strategy, operations improvement, product quality, and revenue cycle management. He has an impressive history of utilizing data driven problem solving (Lean Six Sigma) and project management (PMP and CSM) to achieve strategic goals surrounding customer satisfaction, operational efficiency and improved profit. SMYRNA, Tenn. – Beck/Arnley has announced that Ross Proffitt has joined the company as its new marketing coordinator. In this position, Proffitt will assist with creating sales promotions, execution and fulfillment, as well as coordinating the distribution of marketing materials such as collateral and signage. AdvertisementClick Here to Read MoreAdvertisement Proffitt also will handle the re-launch of Beck/Arnley’s social media campaign. He reports to Paul Farwick, vice president of sales for Beck/Arnley. “I would like to welcome Ross to the Beck/Arnley team and express how excited we are to have him on board to serve as our marketing coordinator,” said Farwick. “He started as an intern with us last summer while he was still in school and worked with us over the winter months. Through his internship, Ross demonstrated that he possess the knowledge and ability to help take our marketing initiatives to a new level. He did such a great job that we knew we wanted him to join us full-time once he graduated from The University of Tennessee-Chattanooga. We look forward to watching Ross grow his involvement and responsibilities with Beck/Arnley.”,Lubrication Specialties Inc. (LSI), manufacturer of Hot Shot’s Secret brand of performance additives and oils, recently announced the expansion of senior leadership. Steve deMoulpied joins LSI as the company’s chief operating officer (COO). AdvertisementClick Here to Read MoreAdvertisement
SFNF News:SANTA FE – The Santa Fe National Forest (SFNF) is preparing for big crowds this Fourth of July holiday weekend as more and more people seek solace from COVID-19 in nature All are welcome, but if you plan to spend the holiday camping, hiking or otherwise enjoying your public lands, please do so responsibly.Although the monsoons are expected soon, New Mexico is still in fire season. Moderate to severe drought conditions with well-below-normal rainfall and above-average temperatures translate to elevated fire risk across northern New Mexico, and fire managers do not expect that to change soon.“What we’ll need to get out of the danger zone is a few weeks of consistent cloudy skies and widespread rain. The fuels in the forest right now are so dry that a few days of rain followed by a hot-dry pattern only gives us a short break,” fire planner Rich Sack said.To help reduce the risk of wildfire, the SFNF is currently under Stage 2 fire restrictions, which include a ban on campfires. Fireworks are always prohibited on national forests and grasslands.“Celebrating the Fourth of July on the national forest is a wonderful tradition for many families,” Acting Forest Supervisor Debbie Cress said. “But this year, gathering around a campfire is not part of that tradition. It takes only one illegal firework or campfire to start a wildfire and put human lives, natural resources and property at risk.”SFNF offices will be closed Friday, July 3, in observance of the Fourth of July holiday, but fire personnel, law enforcement officers and recreation staff will be patrolling the forest over the long weekend.You can be cited for setting off fireworks or building a campfire on the SFNF. The maximum penalty for both is a $5,000 fine and/or up to six months in jail. Anyone who starts a wildfire can also be held liable for the costs associated with putting out the fire.Responsible recreation, especially under COVID-19 conditions, extends beyond fire prevention. Visitors should be prepared to follow “Leave No Trace” principles, including disposing of waste properly and respecting wildlife. Ideally, “pack it in, pack it out” means you take your trash home with you if trash receptacles on the forest are full. Dogs are welcome but must be leashed in developed recreation areas (campgrounds and picnic sites), parking lots and on interpretive trails. Review this recent press release for additional guidance on dog owner’s responsibilities.In the interest of public health and safety, please follow Centers for Disease Control and Prevention (CDC) guidance and comply with state public health orders to protect yourself and others from COVID-19. Avoid crowded areas and park only in designated areas. Do not impede emergency access by blocking roadways, fire lanes or driveways.Stay safe and stay up to date by checking the SFNF website and following the forest on Facebook and Twitter.
The public is invited to a September 25 meeting to comment on the scope of environmental impact statements (EISs) for a proposed coal export terminal near Longview.Millennium Bulk Terminals-Longview LLC proposes to build and operate a terminal to export coal from the site of the former Reynolds Aluminum smelter in Cowlitz County.Cowlitz County, the Washington Department of Ecology (Ecology) and the U.S. Army Corps of Engineers (Corps) are using a synchronized process to create two EISs, one meeting federal requirements and one meeting state requirements. Cowlitz County and Ecology must follow the State Environmental Policy Act (SEPA), and the Corps must follow the National Environmental Policy Act (NEPA).The second of five scoping meetings will be held from 4 to 8 p.m. Sept. 25 at the Spokane Convention Center, 334 W. Spokane Falls Blvd.The first meeting was held in Longview on Sept. 17. Subsequent meetings will be held in Pasco on Oct. 1, Clark County on Oct. 9 and Tacoma on Oct. 17.[mappress]Press Release, September 23, 2013
President Mbeki meeting Dedan Kimathi’s widow. #SABCNEWS pic.twitter.com/GeGtjvryBG— Sarah Kimani (@sarahkimani) April 28, 2017 A Kenyan University has honored former South African President Thabo Mbeki with an honorary degree for his role in liberating South Africa and his part in the African Renaissance, reports SABC.Dedan Kimathi University, named after Kenya’s Mau Mau liberation hero Kimathi, awarded Thabo Mbeki with a Degree of Doctor of Humane Letters (Honoris Causa) during its graduation ceremony.Mbeki: indeed Mandela said during his first visit to Kenya of how much he admired Kimathi and other Kenyan freedom fighters. #SABCNEWS— Sarah Kimani (@sarahkimani) April 28, 2017Mbeki lauded the role of Kenya’s liberation heroes in South Africa’s liberation struggle, urging graduates at the university to emulate and complete the dreams of African forefathers during his speech.President Thabo Mbeki planting a tree at the Africa Heroes Garden before the Graduation Ceremony. pic.twitter.com/HH8DF72yzH— Mbeki Foundation (@TMFoundation_) April 28, 2017 Kenyans out in their numbers to see the African giant on their home soil. #MbekiInKenya #ThaboMbeki #Mbeki @TMFoundation_ AKEKHO OFANA NAYE pic.twitter.com/Xj3eDFDGfq— Asanda Magaqa (@asandamagaqa) April 28, 2017
46 Views no discussions Dr. Didacus Jules; Director General of the OECS (file photo)(Antigua Observer) Students from the United States (US) and the wider Caribbean may soon flock to Antigua & Barbuda if a proposal to establish a joint Organisation of Eastern Caribbean States (OECS) – Cuba medical school on the island ever comes to fruition.While he admitted that the plan was, for the moment “an agreement in principle” among the OECS ministers of health, the Director General of the OECS Dr Didacus Jules spoke optimistically of the proposal at the Antigua & Barbuda Employer’s Federation (ABEF) Breakfast Forum yesterday.“The OECS health ministers have agreed in principle to establish a joint offshore medical school with Cuba to serve the hemisphere and tap the lucrative market for medical training,” Dr Jules said noting that there was a “huge opportunity”.According to Dr Jules, Cuba “has accumulated an immense knowledge base in the treatment of a variety of diseases” and has been declared by the World Health Organization (WHO) as being “a world medical power” making it a worthy competitor in the market of providing medical training.The director general noted that past statistics showed that there was niche market for medical training among US citizens of which some institutions in the Caribbean had long taken advantage.“The market for medical training in the US was growing by US $4 billion a year. And the largest providers – there are 1986 figures – of offshore medial services to the US was St Georges University in Grenada followed by Ross University in Dominica.“So just in the area of producing qualified medical personnel these universities…were niche global players,” he said.At the same time, Dr Jules lamented the speed with which policies of engagement with Cuba have been adopted within the OECS and their member states.He said, “So the question to [the ministers] was why you haven’t all thought of setting up a medical school?”While he acknowledged that the Cuban government has “never been interested in medicine as a capitalist venture” the potential benefits of such co-operation were still growing and Cuban society was changing. NewsRegional OECS-Cuba medical school proposed for Antigua by: – January 27, 2017 Share Share Share Tweet Sharing is caring!